Orion Oyj (OTCMKTS:ORINY) Shares Up 3.7% – Time to Buy?

Shares of Orion Oyj (OTCMKTS:ORINY) traded up 3.7% during mid-day trading on Tuesday . The company traded as high as $22.76 and last traded at $22.76. 296 shares changed hands during trading, a decline of 38% from the average session volume of 478 shares. The stock had previously closed at $21.95.

Orion Oyj Trading Up 3.7 %

The company’s 50-day moving average is $23.13 and its 200 day moving average is $24.15. The company has a current ratio of 2.39, a quick ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market cap of $6.42 billion, a PE ratio of 18.06 and a beta of 0.21.

Orion Oyj (OTCMKTS:ORINY) last released its earnings results on Tuesday, October 29th. The company reported $0.63 earnings per share (EPS) for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The company had revenue of $517.97 million during the quarter. As a group, sell-side analysts predict that Orion Oyj will post 1.18 EPS for the current year.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.